AstaZeneca in patent warning as net profit falls

(AP)—Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 percent fall in full-year net profit on Thursday.

AstraZeneca said that its net profit fell to $6.3 billion in the year ended Dec. 31, compared with nearly $10 billion in 2011. The company blamed the loss of exclusivity on several big-name drugs for a drop in revenue to $28 billion from $33.6 billion a year earlier, and warned it expects the trend to continue hitting sales in 2013.

Chief executive Pascal Soriot said Thursday the company's 2012 performance "reflects a period of significant patent expiry and tough market conditions."

He said AstraZeneca's new leadership team would focus on the company's brands and developmental pipeline.

Patents are crucial assets for pharmaceutical companies, which use them to insulate their expensive, brand-name drugs from competition from cheap, generic versions. Expiring patents on several of AstraZeneca's top drugs translates to weaker revenue as the company cuts prices or surrenders market share.

AtraZeneca reported that U.S. revenue fell 21 percent, largely due to competition from of its anti-depression medication, Seroquel IR, whose patent expired last year.

The company said that nearly two thirds of its 19 percent loss in revenue in Western Europe was the result of generic competition for Seroquel IR, as well as drug Nexium, Atacand, and skin medication Merrem.

In Canada, to cholesterol-control drug Crestor dragged revenue down 31 percent.

The company said it expects challenging market conditions to persist in 2013, with the first quarter of the year expected to be "particularly challenging" since and —in Canada—haven't yet reached a full year since generics entered the market.

At Hargreaves Landsdowne, equity analyst Keith Bowman warned that, unlike other companies in the medical field, AstraZeneca "does not enjoy the cushion of alternative revenue streams such as consumer health care" and noted a "general lack of optimism" surrounding its developmental pipeline.

But Panmure analyst Savvas Neophytou said the results were "not as bad as they could have been," noting that fourth-quarter results were more resilient than expected.

AstraZeneca's fourth-quarter net profit edged higher to 1.52 billion pounds from 1.49 billion pounds in the same period a year earlier, while revenue slipped to 7.3 billion pounds from 8.7 billion pounds.

Stocks in fell 4.8 percent to 30 pounds a share in early morning trading on the London Stock Exchange.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Taiwan's HTC expects 30 percent sales plunge in 1Q

Feb 06, 2012

Taiwan's leading smartphone maker HTC forecast Monday that its revenue in the three months to March may plunge 30 percent from a year ago, as competitors Apple and Samsung take their grip on the market.

Texas Instruments lowers 4Q outlook

Dec 09, 2011

(AP) -- Semiconductor maker Texas Instruments Inc. lowered its outlook for its fourth-quarter revenue and profit on Thursday, saying demand had weakened for a variety of products that use its chips.

Amgen 4Q profit drops 16 pct. on higher spending

Jan 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Recommended for you

Cold cash just keeps washing in from ALS challenge

5 hours ago

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

21 hours ago

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

Mind over matter for people with disabilities

Aug 26, 2014

People with serious physical disabilities are unable to do the everyday things that most of us take for granted despite having the will – and the brainpower – to do so. This is changing thanks to European ...

Ukraine's former world's tallest man dies

Aug 25, 2014

Ukraine's tallest man, who briefly held the world record but gave it up to live as a recluse, has died due to complications from the condition that saw him never stop growing, local media reported Monday.

User comments